{"disease":{"id":"alpha1-antitrypsin-deficiency","name":"alpha1 antitrypsin deficiency"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06512454","title":"A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT07326592","title":"Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":270,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT05677971","title":"Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT00313144","title":"Aralast alpha1-proteinase Inhibitor Surveillance Study","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":127,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT06165341","title":"Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT04474197","title":"Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":true},{"nct_id":"NCT00161707","title":"Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT02525861","title":"GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT05899673","title":"An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":31,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT01651351","title":"GLASSIA Infusion Rate Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT04722887","title":"A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Grifols Therapeutics LLC","has_results":false},{"nct_id":"NCT00157092","title":"Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT02722304","title":"Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT02870348","title":"Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Grifols Therapeutics LLC","has_results":true},{"nct_id":"NCT02870309","title":"Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Grifols Therapeutics LLC","has_results":true},{"nct_id":"NCT06892236","title":"Preparation of IPSC for Cell Gene Editing for the Treatment of AATD","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT05466747","title":"A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT04440488","title":"ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Shire","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}